By Aiden Flynn, Exploristics CEO
Functional service provision can help to buffer the continuous ebb and flow of development pipelines for large drug developers. However, the best FSP offerings can also support the development needs of much smaller organisations. So, …
By Aiden Flynn. Exploristics CEO
With the increasing complexity of clinical trials involving larger quantities of varied data and pressure to deliver better returns on expensive R&D investment, pharmaceutical and biotechnology companies have increased the volume, scope, and types of …
By Kimberley Hacquoil, Exploristics CDSO
Biotechnology companies have recently been plagued with waves of layoffs, longer roads to IPO and increasing difficulty in finding investors to support the new and innovative drug discovery and development plans. Biotech companies who can …
